---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-270953"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2021-09-13T23:59:59+00:00"
generated_at: "2026-06-29T04:08:50.743077+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience appoints Emma Reeve to Board, changes auditor to BDO after reverse merger

## Summary
- Emma Reeve appointed Class III director and Audit Committee Chair, effective Sept 8, 2021.
- Reeve brings experience from Constellation Pharmaceuticals (CFO, oversaw $1.7B sale) and board seats at PTC Therapeutics, Editas Medicine.
- Auditor changed: Ernst & Young dismissed, BDO engaged as independent auditor following reverse merger with Old Aadi; no disagreements or reportable events.
- Company highlights upcoming PDUFA target action date of Nov 26, 2021 for FYARRO (nab-sirolimus) in PEComa.

## SEC filing metadata
- accession: 0001193125-21-270953
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2021-09-13T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 4.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312521270953/0001193125-21-270953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312521270953/d138836d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-270953
- JSON: https://secwatch.observer/filing/0001193125-21-270953.json
- Plain text: https://secwatch.observer/filing/0001193125-21-270953.txt

## Key facts
- Executive change
  Emma Reeve was appointed as Class III Director at Whitehawk Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On September 8, 2021, Emma Reeve was appointed a Class III director by the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312521270953/0001193125-21-270953-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.